Brachytherapy (BT) remains the standard modality for dose escalation in cervical cancer boost targets, with well-established high-dose-rate (HDR) EQD2 constraints based on HR-CTV D90 and organ-at-risk (OAR) D2cc metrics. However, BT is not feasible for all pa...
Faraz KalantariScott CordovaSantanu Samanta
Therapy Physics